نتائج البحث - "Christine Theodore"

1

Very long-term complete remission can be achieved in men with high-risk localized prostate cancer and a very high PSA value: an analysis of the GETUG 12 Phase 3 trial

المصدر: Clinical Genitourinary Cancer.

مصطلحات موضوعية: Oncology, Urology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8978f2b78f6e245c96f06c9d19176e76Test
https://doi.org/10.1016/j.clgc.2023.05.003Test

2

Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study

المساهمون: Medical Oncology, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie

المصدر: European Urology, 80(4), 497-506. Elsevier
European Urology, Vol. 80, no. 4, p. 497-506 (2021)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::855ca63ac5d77345d67181e5d8bdb3a5Test
https://doi.org/10.1016/j.eururo.2021.06.021Test

3

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

المساهمون: Medical Oncology, Institut Gustave Roussy (IGR), Oncologie génito-urinaire, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut Jean Godinot [Reims], UNICANCER, Weill Cornell Medicine [New York], Université Catholique de Louvain = Catholic University of Louvain (UCL), Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Casa Sollievo della Sofferenza [San Giovanni Rotondo] (IRCCS), Fondazione Ospedale San Camillo [Venezia] (IRCCS), Erasmus University Medical Center [Rotterdam] (Erasmus MC), UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie

المصدر: Lancet Oncology, 21(11), 1513-1525. Lancet Publishing Group
Lancet Oncology
Lancet Oncology, Elsevier, 2020, 21, pp.1513-1525. ⟨10.1016/S1470-2045(20)30449-6⟩
The Lancet Oncology, Vol. 21, no. 11, p. 1513-1525 (2020)

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Population, Disease-Free Survival, law.invention, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, SDG 3 - Good Health and Well-being, law, Internal medicine, Nitriles, Phenylthiohydantoin, medicine, Clinical endpoint, Humans, Enzalutamide, 030212 general & internal medicine, Neoplasm Metastasis, education, ComputingMilieux_MISCELLANEOUS, Aged, education.field_of_study, Performance status, business.industry, Androgen Antagonists, Middle Aged, medicine.disease, 3. Good health, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Docetaxel, chemistry, Cabazitaxel, 030220 oncology & carcinogenesis, Benzamides, Androgens, Quality of Life, Androstenes, Taxoids, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1bd2b066feb2208404b38f183755ac8Test
https://pure.eur.nl/en/publications/5fe2d06f-9d36-455e-ab42-4e790199991eTest

4

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma

المساهمون: Sonpavde, Gp, Mariani, L, Lo Vullo, S, Raggi, D, Giannatempo, P, Bamias, A, Crabb, Sj, Bellmunt, J, Yu, Ey, Niegisch, G, Vaishampayan, Un, Theodore, C, Berthold, Dr, Srinivas, S, Sridhar, S, Plimack, Er, Rosenberg, Je, Powles, T, Galsky, Md, Necchi, A

المصدر: Journal of Urology. 200:1207-1214

مصطلحات موضوعية: Male, Oncology, Urologic Neoplasms, medicine.medical_specialty, Urology, Urinary system, medicine.medical_treatment, Platinum Compounds, Kaplan-Meier Estimate, Drug Administration Schedule, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, medicine, Humans, 030212 general & internal medicine, Urothelium, Aged, Neoplasm Staging, Retrospective Studies, Platinum, Cisplatin, Carcinoma, Transitional Cell, Chemotherapy, business.industry, Confounding, Middle Aged, medicine.disease, Carboplatin, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Female, First line chemotherapy, business, medicine.drug

وصف الملف: text

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::426e8a57ed9e8e08455a8b91f6ba0681Test
https://doi.org/10.1016/j.juro.2018.07.035Test

5

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

المؤلفون: Thomas Powles, Michiel S van der Heijden, Daniel Castellano, Matthew D Galsky, Yohann Loriot, Daniel P Petrylak, Osamu Ogawa, Se Hoon Park, Jae-Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J Eigl, Howard Gurney, Som D Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P Fay, Ignacio Duran, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok K Gupta, Wendy Levin, Joaquim Bellmunt, Michiel S. van der Heijden, Jae Lyun Lee, Bernhard J. Eigl, Som D. Mukherjee, Cristina Suarez, Hans Westgeest, Aude Flechon, Yen-Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez-Valderrama, Susanna Cheng, Stephen Frank, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala Sridhar, Giorgio Vittorio Scagliotti, Jens Voortman, Boris Alekseev, Anna Alyasova, Boris Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, Jose Angel Arranz, Djura Piersma, Sang Joon Shin, Oleg Karyakin, Ignacio Delgado, Jose Luis Gonzalez, See-Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, Monserrat Domenech, Yen-Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, Vasileios Georgoulias, Sasja Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott Tagawa, Pawel Zalewski, Florence Joly, Gencay Hatiboglu, Luca Gianni, Franco Morelli, Rosa Tambaro, Yasuhiro Hashimoto, Alexander Nosov, Albert Font, Alejo M. Rodriguez-Vida, Robert Jones, Naveen Vasudev, Sandhya Srinivas, Jingsong Zhang, Thierry Gil, Daygen Finch, Marc-Oliver Grimm, Yu-Li Su, Simon Chowdhury, Christopher Hocking, Eugen Plas, Scott North, Niels Viggo Jensen, Christine Theodore, Florian Imkamp, Avivit Peer, Takashi Kobayashi, Hideki Sakai, Naoto Sassa, Kazuhiro Yoshimura, Maureen Aarts, Ana Ferreira Castro, Marlen Topuzov, Juan Francisco Rodriguez, Federico Jose Vazquez, Yu-Chieh Tsai, Simon Crabb, Syed Hussain, Johanna Bendell, Marine Gross-Goupil, Gravis Gwenaelle, Raanan Berger, Galina Statsenko, Linda Evans, Alexandra Drakaki, Bradley Somer, Ian Davis, James Lynam, Giuliano Borges, Aldo Dettino, André P. Fay, Graziella Martins, Luis Eduardo Zucca, Mads Agerbaek, Haralambos Kalofonos, Eli Rosenbaum, Hideki Enokida, Hiroaki Kikukawa, Kazuo Nishimura, Satoshi Tamada, Motohide Uemura, Yamil Lopez, Jourik Gietema, Marcin Slojewski, Isabel Fernandes, Alexey Smolin, Danish Mazhar, Arash Rezazadeh Kalebasty, Bradley Carthon, Wolfgang Loidl, Fabio Franke, Gustavo Girotto, Nimira Alimohamed, Robyn Macfarlane, Helle Pappot, Guenter Niegisch, Dimitrios Mavroudis, Avishay Sella, Camillo Porta, Shin Ebara, Motonobu Nakamura, Wataru Obara, Norihiko Okuno, Nobuo Shinohara, Mikio Sugimoto, Akitaka Suzuki, Noriaki Tokuda, Hiroji Uemura, Akito Yamaguchi, Francisco Ramirez, Pawel Rozanowski, Pawel Wiechno, Bhumsuk Keam, Nikolay Kislov, Denis Plaksin, Irfan Cicin, Satish Kumar, Matthew D. Galsky, Daniel P. Petrylak, Joseph Rosales, Ulka Vaishampayan, Stephane Culine, Christos Papandreou, Taketoshi Nara, Mustafa Erman, Laurence Kreiger, Juliana Janoski, Diogo Rosa, Mariana Siqueira, Christina Canil, Lisa Sengelov, Jean-Marc Tourani, Gaku Arai, Katsuyoshi Hashine, Mutsushi Kawakita, Noboru Nakaigawa, Hayahito Nomi, Hiroaki Shiina, Hiroyoshi Suzuki, Junji Yonese, Roberto Kuri, Eleazar Macedo, Samuel Rivera, Alberto Villalobos Prieto, Anna Polakiewicz-Gilowska, Renata Zaucha, Fabio Lopes, Roman Ponomarev, Mark Pomerantz, Shahrokh Shariat, Cynthia Luk, Krzysztof Lesniewski-Kmak

المساهمون: Graduate School, CCA - Cancer Treatment and quality of life, Internal medicine, Medical oncology, Powles, T., van der Heijden, M. S., Castellano, D., Galsky, M. D., Loriot, Y., Petrylak, D. P., Ogawa, O., Park, S. H., Lee, J. -L., De Giorgi, U., Bogemann, M., Bamias, A., Eigl, B. J., Gurney, H., Mukherjee, S. D., Fradet, Y., Skoneczna, I., Tsiatas, M., Novikov, A., Suarez, C., Fay, A. P., Duran, I., Necchi, A., Wildsmith, S., He, P., Angra, N., Gupta, A. K., Levin, W., Bellmunt, J., Lee, J. L., Westgeest, H., Flechon, A., Ou, Y. -C., Park, I., Matveev, V., Perez-Valderrama, B., Cheng, S., Frank, S., Anido, U., Hamzaj, A., Retz, M., Sridhar, S., Scagliotti, G. V., Voortman, J., Alekseev, B., Alyasova, A., Komyakov, B., Dumez, H., Pavic, M., Kimura, G., Mizokami, A., Osanto, S., Arranz, J. A., Piersma, D., Shin, S. J., Karyakin, O., Delgado, I., Gonzalez, J. L., Pang, S. -T., Tran, A., Lipatov, O., Su, W. -P., Flaig, T., Alva, A., Park Kyong, H., Kopyltsov, E., Almagro, E., Domenech, M., Chang, Y. -H., Sautois, B., Ravaux, A., Aravantinos, G., Georgoulias, V., Mulder, S., Kim, Y. J., Kater, F., Chevreau, C., Tagawa, S., Zalewski, P., Joly, F., Hatiboglu, G., Gianni, L., Morelli, F., Tambaro, R., Hashimoto, Y., Nosov, A., Font, A., Rodriguez-Vida, A. M., Jones, R., Vasudev, N., Srinivas, S., Zhang, J., Gil, T., Finch, D., Grimm, M. -O., Su, Y. -L., Chowdhury, S., Hocking, C., Plas, E., North, S., Jensen, N. V., Theodore, C., Imkamp, F., Peer, A., Kobayashi, T., Sakai, H., Sassa, N., Yoshimura, K., Aarts, M., Ferreira Castro, A., Topuzov, M., Rodriguez, J. F., Vazquez, F. J., Tsai, Y. -C., Crabb, S., Hussain, S., Bendell, J., Gross-Goupil, M., Gwenaelle, G., Berger, R., Statsenko, G., Evans, L., Drakaki, A., Somer, B., Davis, I., Lynam, J., Borges, G., Dettino, A., Martins, G., Zucca, L. E., Agerbaek, M., Kalofonos, H., Rosenbaum, E., Enokida, H., Kikukawa, H., Nishimura, K., Tamada, S., Uemura, M., Lopez, Y., Gietema, J., Slojewski, M., Fernandes, I., Smolin, A., Mazhar, D., Kalebasty, A. R., Carthon, B., Loidl, W., Franke, F., Girotto, G., Alimohamed, N., Macfarlane, R., Pappot, H., Niegisch, G., Mavroudis, D., Sella, A., Porta, C., Ebara, S., Nakamura, M., Obara, W., Okuno, N., Shinohara, N., Sugimoto, M., Suzuki, A., Tokuda, N., Uemura, H., Yamaguchi, A., Ramirez, F., Rozanowski, P., Wiechno, P., Keam, B., Kislov, N., Plaksin, D., Cicin, I., Kumar, S., Rosales, J., Vaishampayan, U., Culine, S., Papandreou, C., Nara, T., Erman, M., Kreiger, L., Janoski, J., Rosa, D., Siqueira, M., Canil, C., Sengelov, L., Tourani, J. -M., Arai, G., Hashine, K., Kawakita, M., Nakaigawa, N., Nomi, H., Shiina, H., Suzuki, H., Yonese, J., Kuri, R., Macedo, E., Rivera, S., Villalobos Prieto, A., Polakiewicz-Gilowska, A., Zaucha, R., Lopes, F., Ponomarev, R., Pomerantz, M., Shariat, S., Luk, C., Lesniewski-Kmak, K., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE)

المصدر: lancet oncology, 21(12), 1574-1588. Lancet Publishing Group
Lancet Oncology, 21(12), 1574-1588. Lancet Publishing Group
DANUBE study investigators & Voortman, J 2020, ' Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE) : a randomised, open-label, multicentre, phase 3 trial ', Lancet Oncology, vol. 21, no. 12, pp. 1574-1588 . https://doi.org/10.1016/S1470-2045Test(20)30541-6
The Lancet Oncology, 21(12), 1574-1588. ELSEVIER SCIENCE INC

مصطلحات موضوعية: 0301 basic medicine, Male, medicine.medical_specialty, Urologic Neoplasms, Durvalumab, Time Factors, medicine.medical_treatment, Population, Neutropenia, Antibodies, Monoclonal, Humanized, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, education, Immune Checkpoint Inhibitors, Aged, Chemotherapy, education.field_of_study, business.industry, Hazard ratio, Carcinoma, Antibodies, Monoclonal, Middle Aged, medicine.disease, Gemcitabine, Carboplatin, 030104 developmental biology, Treatment Outcome, Oncology, chemistry, 030220 oncology & carcinogenesis, Female, Urothelium, business, Tremelimumab, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d1a55ae19ca8e730510c641cbd9a05aTest
https://pubmed.ncbi.nlm.nih.gov/33387509Test

6

PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY

المؤلفون: Jean-Christophe Eymard, Cora N. Sternberg, Ásgerður Sverrisdóttir, Carole Helissey, Roberto Iacovelli, Ronald de Wit, Ayse Ozatilgan, Christine Theodore, Daniel Castellano, Christine Geffriaud-Ricouard, Bertrand Tombal, Bohuslav Melichar, Johann S. de Bono, Joan Carles, Gero Kramer, Michail Liontos, Christian Wülfing, Susan Feyerabend, Karim Fizazi

المصدر: Journal of Urology. 203

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Urology, Castration resistant, medicine.disease, chemistry.chemical_compound, Prostate cancer, Abiraterone, chemistry, EQ-5D, Cabazitaxel, Internal medicine, Enzalutamide, Medicine, In patient, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::eac0b937bb8088072e3098b8acc271fcTest
https://doi.org/10.1097/ju.0000000000000859.08Test

7

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial

المساهمون: Diallo, Ousseynatou, Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

المصدر: European Urology
European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩

مصطلحات موضوعية: Male, Oncology, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Docetaxel, Kaplan-Meier Estimate, Androgen deprivation therapy, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Belgium, Medicine, 030212 general & internal medicine, Neoplasm Metastasis, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Middle Aged, Prognosis, [SDV] Life Sciences [q-bio], Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, 030220 oncology & carcinogenesis, France, medicine.drug, medicine.medical_specialty, Maximum Tolerated Dose, Bicalutamide, Urology, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Internal medicine, Confidence Intervals, Humans, Enzalutamide, Neoplasm Invasiveness, Aged, Neoplasm Staging, Retrospective Studies, Chemotherapy, Dose-Response Relationship, Drug, business.industry, Androgen Antagonists, Prostate-Specific Antigen, medicine.disease, Survival Analysis, Confidence interval, Castration, chemistry, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1040aebf886696a2b0d18501c3ffa7feTest
https://doi.org/10.1016/j.eururo.2017.09.022Test

8

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

المساهمون: Medical Oncology, Institut Català de la Salut, [de Wit R] Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands. [Wülfing C] Department of Urology, Asklepios Tumorzentrum, Hamburg, Germany. [Castellano D] Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain. [Kramer G] Department of Urology, Medical University of Vienna, Vienna, Austria. [Eymard JC] Department of Medical Oncology, Institute Jean Godinot, Reims, France. [Sternberg CN] Division of Hematology and Medical Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, USA. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie

المصدر: ESMO Open, 6(5):100241. BMJ Publishing Group
Scientia
ESMO Open
ESMO open, Vol. 6, no. 5, p. 100241 [1-9] (2021)

مصطلحات موضوعية: Male, Oncology, Cancer Research, Neutrophils, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Prostate cancer, chemistry.chemical_compound, abiraterone, Antineoplastic Combined Chemotherapy Protocols, Medicine, Lymphocytes, prognostic factor, Original Research, enzalutamide, Hazard ratio, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Prognosis, Prostatic Neoplasms, Castration-Resistant, Docetaxel, Cabazitaxel, Benzamides, Biomarker (medicine), Androstenes, Taxoids, medicine.drug, medicine.medical_specialty, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Quimioteràpia combinada, SDG 3 - Good Health and Well-being, neutrophil-to-lymphocyte ratio, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, Nitriles, Phenylthiohydantoin, Humans, Pròstata - Càncer - Prognosi, Enzalutamide, Neutrophil to lymphocyte ratio, Diagnosis::Prognosis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], business.industry, fungi, cabazitaxel, Pròstata - Càncer - Tractament, medicine.disease, Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant [DISEASES], Confidence interval, metastatic castration-resistant prostate cancer, chemistry, neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración [ENFERMEDADES], business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b88349c3a937b74a86f31dd44753d3Test
https://doi.org/10.1016/j.esmoop.2021.100241Test

9

713P Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial

المصدر: Annals of Oncology. 32:S719

مصطلحات موضوعية: Poor prognosis, chemistry.chemical_compound, Oncology, chemistry, Pulmonary toxicity, business.industry, Cancer research, medicine, Hematology, Germ cell tumors, medicine.disease, business, Bleomycin

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::a22f6baaeb3f9a998112777c692aa422Test
https://doi.org/10.1016/j.annonc.2021.08.109Test

10

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

المصدر: European Journal of Cancer. 87:140-146

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Poor prognosis, Time Factors, medicine.medical_treatment, Radiography, Kaplan-Meier Estimate, Bleomycin, Disease-Free Survival, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Testicular Neoplasms, Risk Factors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Multicenter Studies as Topic, Etoposide, Proportional Hazards Models, Retrospective Studies, Cisplatin, Chemotherapy, Brain Neoplasms, business.industry, Neoplasms, Germ Cell and Embryonal, Magnetic Resonance Imaging, United States, Surgery, Regimen, Treatment Outcome, 030104 developmental biology, medicine.anatomical_structure, Clinical Trials, Phase III as Topic, chemistry, 030220 oncology & carcinogenesis, Disease Progression, France, Tomography, X-Ray Computed, business, Germ cell, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a877563622d354ceb529601e20d92889Test
https://doi.org/10.1016/j.ejca.2017.09.029Test

تنقيح النتائج